Skip Navigation


European Heart Journal Advance Access originally published online on January 11, 2005
European Heart Journal 2005 26(3):203-206; doi:10.1093/eurheartj/ehi118
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/3/203    most recent
ehi118v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McMurray, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMurray, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal vol. 26 no. 3 © The European Society of Cardiology 2005; all rights reserved.

Making sense of SENIORS

John McMurray*

Department of Cardiology, Western Infirmary, Glasgow G11 6NT, UK

* Tel: +44 141 211 1838; fax: +44 141 211 2252. E-mail address: j.mcmurray@bio.gla.ac.uk

This editorial refers to ‘Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)’{dagger} by M.D. Flather et al., on page 215

The first 10% of the full text of this article appears below.

Recently, three landmark, prospective, randomized, placebo-controlled trials demonstrated, unequivocally, that a relatively short period of treatment with certain beta-blockers (bisoprolol, target dose 10 mg once daily; carvedilol, target dose 25 mg twice daily; and metroprolol CR/XL, target dose 200 mg once daily) led to a comparable reduction in the risk of death (relative risk reduction ~33%) in patients with chronic heart failure (CHF) and a reduced left ventricular ejection fraction (LVEF).1–3 The decrease in mortality in these trials due, mainly, to a pronounced reduction in death from cardiovascular causes, was seen irrespective of symptom severity and was accompanied by similarly large . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
Marcus D. Flather, Marcelo C. Shibata, Andrew J.S. Coats, Dirk J. Van Veldhuisen, Aleksandr Parkhomenko, Joszef Borbola, Alain Cohen-Solal, Dan Dumitrascu, Roberto Ferrari, Philippe Lechat, Jordi Soler-Soler, Luigi Tavazzi, Lenka Spinarova, Jiri Toman, Michael Böhm, Stefan D. Anker, Simon G. Thompson, Philip A. Poole-Wilson, and on behalf of the SENIORS Investigators
EHJ 2005 26: 215-225. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
D. Dobre, D. J. van Veldhuisen, M. J.L. DeJongste, C. Lucas, G. Cleuren, R. Sanderman, A. V. Ranchor, and F. M. Haaijer-Ruskamp
Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival
Eur J Heart Fail, March 1, 2007; 9(3): 280 - 286.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D. G. Le Couteur, L. Bailey, and V. Naganathan
Beta-blockers and heart failure in older people
Eur. Heart J., April 1, 2006; 27(7): 887 - 888.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
P. C. Burger and H. B.-L. Rocca
Pharmacotherapy of Congestive Heart Failure in Elderly Patients
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 85 - 94.
[Abstract] [PDF]